Plasma Selenium Levels and Risk of New-Onset Diabetes in Hypertensive Adults.
Yuanyuan Zhang,Huan Li,Tengfei Lin,Huiyuan Guo,Chongfei Jiang,Liling Xie,Youbao Li,Ziyi Zhou,Yun Song,Binyan Wang,Chengzhang Liu,Lishun Liu,Jianping Li,Yan Zhang,Guobao Wang,Min Liang,Yimin Cui,Yong Huo,Yan Yang,Wenhua Ling,Jian Yang,Xiaobin Wang,Hao Zhang,Xianhui Qin,Xiping Xu
DOI: https://doi.org/10.1016/j.jtemb.2019.07.003
2019-01-01
Abstract:OBJECTIVE:The association between plasma selenium and new-onset diabetes in hypertensive adults is still unclear. We aimed to evaluate the relationship of baseline plasma selenium with new-onset diabetes and examine possible effect modifiers in a post-hoc analysis of the China Stroke Primary Prevention Trial (CSPPT).METHODS:A total of 2367 hypertensive, non-diabetic patients with plasma selenium measurements at baseline were included. The primary outcome was new-onset diabetes, defined as physician-diagnosed diabetes or use of glucose-lowering drugs during the follow-up period, or fasting glucose (FG) ≥126.0 mg/dL at the exit visit.RESULTS:At baseline, higher FG levels were found among participants with plasma selenium in quartile 4 (≥94.8 μg/L) (β, 1.64 mg/dL; 95%CI: 0.54, 2.73) compared to those in quartiles 1-3. During a median follow-up duration of 4.5 years, new-onset diabetes occurred in 270 (11.4%) participants. Graphic plot showed a positive association between baseline selenium levels and risk of new-onset diabetes. This was further confirmed by adjusted regression analyses; the odds ratios (OR) for new-onset diabetes comparing quartile 4 (≥94.8 μg/L) to quartiles 1-3 was 1.36 (95%CI: 1.01, 1.83). No clear trend was evident across quartiles 1-3.CONCLUSIONS:Our data suggest that high plasma selenium (≥94.8 μg/L) was associated with increased risk of new-onset diabetes in hypertensive patients.